Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q4 2024 Earnings Presentation
9 slides from Avita Medical's earnings presentation, Feb 14, 2025
Slide 1: Q4 2024 Earnings Presentation
For personal use only Q4 2024 Earnings Presentation February 13, 2025
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this pre
Slide 3: Who We Are: Accelerated Recovery with Therapeutic Acute Wound Care
WHO WE ARE Accelerated Recovery with Therapeutic Acute Wound Care OUR MISSION ACUTE WOUNDS For personal use only Our mission is to position AVITA Medical as a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, ef
Slide 4: RECELL at the Core of a Comprehensive Portfolio
THERAPEUTIC ACUTE WOUND CARE RECELL at the Core of a Comprehensive Portfolio Continuum Of Burn And Full-thickness Skin Defect Wound Care For personal use only Flagship Device Wound Depth Wound Bed Wound Bed Dermal Dressings Wound Scar Assessment Preparation / Hemostasis Replacements / Epidermal Redu
Slide 5: First Patient Treated with Cohealyx
FIRST PATIENT TREATED WITH COHEALYX A Breakthrough in Acute Wound Care DAY 1: DAY 7: DAY 10: Cohealyx Application Post-Cohealyx Application 3-DAYS POST-MSTSG For personal use only A C D B C P5 Performed by Dr. John Loftus of Ohio State University Wexner Medical Center
Slide 6: First Cohealyx Case: Media & Surgeon Feedback
FIRST COHEALYX CASE Media & Surgeon Feedback For personal use only “The ability to facilitate quicker wound closure may reduce the amount of time patients spend in the hospital and improve health outcomes” —John Loftus, MD, Ohio State University P6
Slide 7: AVITA Medical Portfolio: Product Compatibility and Revenue Potential
AVITA MEDICAL PORTFOLIO Product Compatibility and Revenue Potential Our TAM expands from Two-Stage Procedure: Full-Thickness Wound $450 million to $1.5 billion in burn market alone For personal use only TBSA: 10% to 20% Potential Revenue Per Patient3 PermeaDerm $2,000 – $4,000 Dressing RECELL1 $6,50
Slide 8: Annual Commercial Revenue
Annual Commercial Revenue YEAR-OVER-YEAR GROWTH For personal use only $120 70% $103.01 $100 60% Commercial Revenue (in millions 61% Year-Over-Year Growth 50% $80 $64.1 40% $60 $49.8 29% 30% 46% $40 $34.1 20% $25.1 36% $20 $17.6 43% 10% $0 0% Ryan Zimmerman, BTIG (U.S.)2020 2021 2022 2023 Scott 2
Slide 9: For personal use only
For personal use only